Heartflow, Inc. Common Stock (HTFL) - Stock Analysis
Last updated: Apr 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
HeartFlow (HTFL) has multiple fresh growth catalystsâAetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000âpatient NAVIGATEâPCI registry on March 16, 2026âand its stock has surged ~20â30% off the March low, positioning it as a highâbeta, event-driven healthcare IT momentum trade despite ongoing operating losses.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margin ⢠Severe operating loss ⢠Healthy liquidity HTFL pairs high revenue and very strong gross margins with outsized opex-driven losses and cash burnâbalance sheet and investments provide runway, but current valuation is rich and the investment case depends on rapid operating/cash-flow improvement.
Price Behavior
Key Price Behavior Insights: ⢠Sideways consolidation ⢠Sharp midâmonth rebound ⢠Failed followâthrough Support Level: $20.98 Resistance Level: $27.97 Over the last month HTFL traded sideways around $24.8 after a sharp rebound from $20.98 to $27.97 that reclaimed about half the drawdown, indicating support in the low-$20s, resistance near the high-$27s, and elevated shortâterm volatility.
Sentiment & News
Key News Insights: ⢠Revenue growth ⢠Guidance uplift ⢠Institutional interest HeartFlow reported strong 2025 commercial and clinical momentumâQ4 revenue +40% y/y and FY >$176M, guided ~25% revenue growth for 2026 with improving margins, rising institutional stakes, and some insider selling.
AI Summary
HTFL has shifted from a speculative clinicalâstory to an operationally scalable businessâdurable ~80% gross margins plus Plaque Analysis reimbursement make converting installedâbase monetization into positive operating cash flow the decisive investment hinge, because failure to materially narrow cash burn or accelerate adoption would force dilutive capital raises and trigger sharp multiple compression.
Description
HeartFlow offers a non-invasive diagnostic platform that converts a single coronary CT angiogram into a patient-specific 3D heart model and applies computational fluid dynamics and related analytics to quantify blood flow, arterial narrowing, and plaque characteristics. Founded in 2007 and based in Mountain View, California, the company distributes its technology globally to support clinical assessment and management of coronary artery disease.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 23 | Mar 30 | HTFL | Heartflow, Inc. Common Stock | HeartFlow (HTFL) has multiple fresh growth catalystsâAetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000âpatient NAVIGATEâPCI registry on March 16, 2026âand its stock has surged ~20â30% off the March low, positioning it as a highâbeta, event-driven healthcare IT momentum trade despite ongoing operating losses. | Closed | -11.0% |